A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer
Authors:
Open Access
- 2 December 2025
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1848
Abstract
Background Small cell lung cancer (SCLC) is known for its highly invasive nature and low 5-year survival rate. Although immunotherapy has shown enhancements in survival among SCLC patients, there is a call for improved precision in targeting beneficiary populations. The development of the Delta-like ligand 3 (DLL3)-targeted drug Rovalpituzumab Tesirine (Rova-T) was halted due to insufficient efficacy, prompting a closer examination of factors influencing treatment effectiveness. This study aims to create a prognostic model for SCLC patients based on protein expression levels to enhance prognosis determination and guide clinical decision-making. cal or histopathological examination from March 13, 2017 to March 12, 2022 in Changzhi People's Hospital, Shanxi were enrolled. The study had specific criteria forKeywords
Funding Information
- Changzhi People's Hospital (202003)
This publication has 60 references indexed in Scilit:
- Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancerBiomedicine & Pharmacotherapy, 2023
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Targeting TREM2 on tumor-associated macrophages enhances immunotherapyCell Reports, 2021
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyJournal of Thoracic Oncology, 2021
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆Annals of Oncology, 2021
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesJournal of Thoracic Oncology, 2020
- PD-L1 expression in small cell neuroendocrine carcinomasEuropean Journal of Cancer, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992